AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8919895 — intervention group
Group type: COMPARATOR
Intervention: Customarily prescribed pain management
Number of subjects: 75
Study 1717669 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhenium-186(Sn)HEDP, single intravenous administration of 30-35 mCi (1110-1295 MBq)
Number of subjects: 0
Study 1717669 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-methylene diphosphonate (MDP) as a radioactive placebo
Number of subjects: 0
Study 7118361 — intervention group
Group type: EXPERIMENTAL
Intervention: jejunoileal bypass
Number of subjects: 134
Study 7118361 — intervention group
Group type: COMPARATOR
Intervention: dietary treatment
Number of subjects: 134
Study 31111884 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model (IVY) predicting FH pregnancy from time-lapse videos
Number of subjects: 10638
Study 31111884 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model (IVY) across different laboratories
Number of subjects: 10638
Study 28079136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 2207
Study 25428394 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 implantation (n = 35)
Number of subjects: 71
Study 25428394 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (n = 36)
Number of subjects: 71
Study 25428394 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 implantation
Number of subjects: 71
Study 25428394 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy and chemotherapy
Number of subjects: 71
Study 23313208 — intervention group
Group type: EXPERIMENTAL
Intervention: Memokath 044TW stent
Number of subjects: 92
Study 23313208 — intervention group
Group type: COMPARATOR
Intervention: Short-term urethral catheter diversion (control)
Number of subjects: 92
Study 20971461 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin wrinkles assessment using the Lemperle wrinkle scale
Number of subjects: 0
Study 20971461 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin rigidity assessment using a durometer
Number of subjects: 0
Study 20971461 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of skin wrinkles with chronological age
Number of subjects: 0
Study 20971461 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of skin rigidity with time since menopause
Number of subjects: 0
Study 20971461 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of weight with skin wrinkling
Number of subjects: 0
Study 19786658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg orally) plus letrozole (2.5 mg orally)
Number of subjects: 219
Study 19786658 — intervention group
Group type: COMPARATOR
Intervention: Letrozole and placebo
Number of subjects: 219
Study 19786658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus letrozole
Number of subjects: 219
Study 16716491 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal non-closure
Number of subjects: 45
Study 16716491 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal closure
Number of subjects: 45
Study 15550024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg day(-1))
Number of subjects: 184
Study 15550024 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg day(-1))
Number of subjects: 184
Study 15550024 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 184
Study 11501686 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted preventive intervention for families with parental depression; details on dosage and duration not available.
Number of subjects: 0
Study 1626493 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis (digoxin), specific dosage and duration not mentioned
Number of subjects: 0
Study 1626493 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 24
Study 6143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 6143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 24
Study 6143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Metoprolol
Number of subjects: 24
Study 6143666 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 24
Study 6143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric and dynamic exercise
Number of subjects: 24
Study 6143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol and Propranolol
Number of subjects: 24
Study 30661699 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed
Number of subjects: 77
Study 30661699 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 77
Study 30661699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 29474294 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident-constructed, low-cost, low-fidelity pelvic model simulation training
Number of subjects: 20
Study 27503644 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-239
Number of subjects: 0
Study 23806276 — intervention group
Group type: EXPERIMENTAL
Intervention: Single incision group (SIG)
Number of subjects: 60
Study 23806276 — intervention group
Group type: COMPARATOR
Intervention: Multiple incision group (MIG)
Number of subjects: 60
Study 23806276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 22325974 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in depression (measured by Patient Health Questionnaire‐9)
Number of subjects: 134
Study 22325974 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in anxiety (measured by Hospital Anxiety and Depression Scale, Anxiety subscale)
Number of subjects: 134
Study 19732481 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparator group (escitalopram or citalopram)
Number of subjects: 20
Study 19732481 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled group (escitalopram or placebo)
Number of subjects: 20
Study 18000087 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (150 microg/h)
Number of subjects: 9
Study 18000087 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study 16430017 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite (Tetric Ceram)
Number of subjects: 63
Study 16430017 — intervention group
Group type: COMPARATOR
Intervention: Calcium aluminate cement
Number of subjects: 63
Study 14638581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg/day
Number of subjects: 384
Study 10405943 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate therapy (400 mg for 14 days followed by 76 days of calcium carbonate 500 mg, repeated every 3 months)
Number of subjects: 61
Study 10405943 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (500 to 1000 mg daily)
Number of subjects: 61
Study 8889726 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 204
Study 8889726 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 204
Study 1877455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cronassial (mixed gangliosides), 40 mg daily intramuscular injection for 4 or 8 weeks
Number of subjects: 58
Study 3906461 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 3-mg dose
Number of subjects: 60
Study 3906461 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 5-mg dose
Number of subjects: 60
Study 3906461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29924746 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training using traditional equipment (EX)
Number of subjects: 34
Study 29924746 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training using traditional equipment and low-dose testosterone supplementation (ExT)
Number of subjects: 34
Study 29924746 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise using a combined resistance and aerobic flywheel device
Number of subjects: 34
Study 29924746 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (CONT)
Number of subjects: 34
Study 29924746 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups (EX, ExT, combined device)
Number of subjects: 34
Study 27591218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 30
Study 27591218 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (NoET)
Number of subjects: 30
Study 25092781 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) with standard chemotherapy (3 mg/m2/dose, administered once in induction course 1 and once in intensification course 2)
Number of subjects: 1022
Study 25092781 — intervention group
Group type: COMPARATOR
Intervention: Standard five-course chemotherapy alone
Number of subjects: 1022
Study 25092781 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) with standard chemotherapy
Number of subjects: 1022
Study 23884390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU/d cholecalciferol for 9 weeks)
Number of subjects: 48
Study 23884390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23884390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 48
Study 21694630 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Draw Intervention Program
Number of subjects: 58
Study 18699936 — intervention group
Group type: EXPERIMENTAL
Intervention: IVX-0142 (80 mg)
Number of subjects: 19
Study 18699936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16527229 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment according to the CAPT protocol
Number of subjects: 30
Study 16527229 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (no treatment)
Number of subjects: 30
Study 16527229 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treated vs control eyes
Number of subjects: 30
Study 12953133 — intervention group
Group type: EXPERIMENTAL
Intervention: RIST (cladribine 0.11 mg/kg/day for 6 days, busulfan 4 mg/kg/day for 2 days, rabbit anti-thymocyte globulin 2.5 mg/kg/day for 2-4 days)
Number of subjects: 50
Study 12953133 — intervention group
Group type: EXPERIMENTAL
Intervention: RIST
Number of subjects: 50
Study 12953133 — intervention group
Group type: COMPARATOR
Intervention: CST
Number of subjects: 50
Study 10761956 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected aspirin use for at least 180 days/year
Number of subjects: 18496
Study 10761956 — intervention group
Group type: COMPARATOR
Intervention: Self-selected aspirin use for 0 to 13 days/year
Number of subjects: 18496
Study 8622072 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (tumorectomy and breast irradiation)
Number of subjects: 179
Study 8622072 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 179
Study 8622072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node irradiation
Number of subjects: 179
Study 8622072 — intervention group
Group type: COMPARATOR
Intervention: No further regional treatment
Number of subjects: 179
Study 1281030 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 52
Study 6386275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg daily
Number of subjects: 17
Study 6386275 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 3 mg daily
Number of subjects: 17
Study 6386275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31122267 — intervention group
Group type: EXPERIMENTAL
Intervention: DICE method
Number of subjects: 150
Study 31122267 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 150
Study 30594236 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Academic Support (EAS)
Number of subjects: 120
Study 30594236 — intervention group
Group type: COMPARATOR
Intervention: Business as usual support
Number of subjects: 120
Study 27217309 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual relationships with teachers and peers
Number of subjects: 111
Study 27217309 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom quality
Number of subjects: 111
Study 27217309 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality classrooms
Number of subjects: 111
Study 24750038 — intervention group
Group type: EXPERIMENTAL
Intervention: Audible alarm condition
Number of subjects: 27
Study 24750038 — intervention group
Group type: COMPARATOR
Intervention: No audible alarm condition (Control)
Number of subjects: 27
Study 21805305 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea-lime-treated rice straw
Number of subjects: 4
Study 21805305 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% urea in concentrate
Number of subjects: 4
Study 21805305 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea-lime-treated rice straw and 4% urea in concentrate
Number of subjects: 4
Study 19851298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-citrulline (6 g/day)
Number of subjects: 17
Study 19851298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18044728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-based immunosuppression
Number of subjects: 30
Study 18044728 — intervention group
Group type: COMPARATOR
Intervention: CNI-based immunosuppression
Number of subjects: 30
Study 15632034 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT in patients with known malignancy
Number of subjects: 88
Study 15632034 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT in patients without known malignancy
Number of subjects: 88
Study 15632034 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT with SUV threshold of 2.3 in patients with known malignancy
Number of subjects: 88
Study 15632034 — intervention group
Group type: COMPARATOR
Intervention: Granulomatous diseases causing false positives in patients without known malignancy
Number of subjects: 88
Study 12739328 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of high-risk patients with genetic predispositions to thrombosis
Number of subjects: 0
Study 10482210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet initiated after a 36-hour fast
Number of subjects: 17
Study 10482210 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory electroencephalogram
Number of subjects: 17
Study 10482210 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (dextrose), 60 g/d
Number of subjects: 17
Study 8845475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular granisetron
Number of subjects: 120
Study 8845475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous granisetron
Number of subjects: 120
Study 1964663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin) administered subcutaneously at a dose of 2 X 150 anti‐Xa units/kg body weight, n = 24
Number of subjects: 50
Study 1964663 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin administered intravenously by continuous infusion at a dose of 450 anti‐Xa units/kg body weight daily for 10 days, n = 26
Number of subjects: 50
Study 1964663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin)
Number of subjects: 50
Study 1964663 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 50
Study 1964663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 50
Study 540524 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine (25 mg 3-times daily for 4 weeks)
Number of subjects: 29
Study 540524 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (25 mg 3-times daily for 4 weeks)
Number of subjects: 29
Study 30414453 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 652
Study 30414453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (historical control group)
Number of subjects: 652
Study 28348164 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlicensed HIV prevention technology
Number of subjects: 382
Study 28348164 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-trial access study
Number of subjects: 382
Study 25534231 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 120
Study 25534231 — intervention group
Group type: COMPARATOR
Intervention: Mini-laparotomy
Number of subjects: 120
Study 23875721 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (trauma focus)
Number of subjects: 70
Study 23875721 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (sexual schema focus)
Number of subjects: 70
Study 23875721 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (both interventions)
Number of subjects: 70
Study 20976480 — intervention group
Group type: EXPERIMENTAL
Intervention: Spicy diet
Number of subjects: 67
Study 20976480 — intervention group
Group type: COMPARATOR
Intervention: Spice-free diet (Control)
Number of subjects: 67
Study 20027366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten
Number of subjects: 0
Study 20027366 — intervention group
Group type: COMPARATOR
Intervention: Grandaxin
Number of subjects: 0
Study 16542133 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient‐centered Assessment and Counseling for Exercise (PACE) protocol
Number of subjects: 96
Study 16542133 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 96
Study 12955426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban therapy in addition to aspirin and heparin therapy
Number of subjects: 83
Study 12955426 — intervention group
Group type: COMPARATOR
Intervention: Heparin therapy alone
Number of subjects: 83
Study 10871828 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1b (Betaferon) 8 MIU subcutaneous every other day
Number of subjects: 304
Study 10871828 — intervention group
Group type: COMPARATOR
Intervention: Interferon-beta-1a (Rebif) 6 MIU subcutaneous once a week
Number of subjects: 304
Study 10871828 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 304
Study 9378843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.25 mg/kg
Number of subjects: 8
Study 9378843 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam 2 mg
Number of subjects: 8
Study 8402492 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12915 at 0.25 mg/kg
Number of subjects: 26
Study 8402492 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12915 at 0.50 mg/kg
Number of subjects: 26
Study 8402492 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12915 at 1.0 mg/kg
Number of subjects: 26
Study 8402492 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12915 at 2.0 mg/kg
Number of subjects: 26
Study 8402492 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12915
Number of subjects: 26
Study 2428266 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Human Albumin (HA)
Number of subjects: 30
Study 2428266 — intervention group
Group type: COMPARATOR
Intervention: 6% Hydroxyethyl Starch (HES)
Number of subjects: 30
Study 29024323 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (60 g)
Number of subjects: 7
Study 29024323 — intervention group
Group type: COMPARATOR
Intervention: Control (phenolic-low diet)
Number of subjects: 7
Study 27302238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment plus usual care
Number of subjects: 496
Study 27302238 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 496
Study 24607027 — intervention group
Group type: EXPERIMENTAL
Intervention: Early routine eptifibatide (n = 1,042)
Number of subjects: 2066
Study 24607027 — intervention group
Group type: COMPARATOR
Intervention: Delayed provisional eptifibatide (n = 1,024)
Number of subjects: 2066
Study 24607027 — intervention group
Group type: EXPERIMENTAL
Intervention: Early routine eptifibatide
Number of subjects: 2066
Study 24607027 — intervention group
Group type: COMPARATOR
Intervention: Delayed provisional eptifibatide
Number of subjects: 2066
Study 22892167 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachway
Number of subjects: 0
Study 22892167 — intervention group
Group type: COMPARATOR
Intervention: Airway Scope
Number of subjects: 0
Study 20420057 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐SE etch (additional enamel etching)
Number of subjects: 38
Study 20420057 — intervention group
Group type: COMPARATOR
Intervention: C‐SE non‐etch (without additional enamel etching)
Number of subjects: 38
Study 18427536 — intervention group
Group type: EXPERIMENTAL
Intervention: Halidor preparation (100 mg, 3 times daily)
Number of subjects: 44
Study 18427536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no halidor)
Number of subjects: 44
Study 14707322 — intervention group
Group type: EXPERIMENTAL
Intervention: tizanidine (150 microg/kg)
Number of subjects: 14
Study 14707322 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 11331627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exogenous FSH (75 IU/day) started on cycle day 3
Number of subjects: 40
Study 11331627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exogenous FSH (75 IU/day) started on cycle day 5
Number of subjects: 40
Study 11331627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exogenous FSH (75 IU/day) started on cycle day 7
Number of subjects: 40
Study 11331627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exogenous FSH (75 IU/day) for all groups
Number of subjects: 40
Study 9142562 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up exercise of 25 min duration and mild intensity
Number of subjects: 0
Study 9142562 — intervention group
Group type: COMPARATOR
Intervention: Warm-up exercise of 45 min duration and intense intensity
Number of subjects: 0
Study 7515706 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of magnesium sulfate intravenously before cardiopulmonary bypass (CPB)
Number of subjects: 140
Study 7515706 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of magnesium soon after CPB
Number of subjects: 140
Study 7515706 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of magnesium before and after CPB
Number of subjects: 140